Most cited papers from CNS Healthcare

CNS Healthcare

What are the most cited papers from CNS Healthcare?

The most cited paper from CNS Healthcare is "Emotional Dysregulation in Adult ADHD and Response to Atomoxetine" (Frederick W. Reimherr, Barrie K. Marchant, Robert E. Strong et al., 2005), with 261 citations. Next come "Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study" (184) and "Multisite Controlled Study of OROS Methylphenidate in the Treatment of Adolescents With Attention-Deficit/Hyperactivity Disorder" (160).

Published TypeFieldAccessCitations

Showing 34 of 34 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Emotional Dysregulation in Adult ADHD and Response to Atomoxetine Frederick W. Reimherr, Barrie K. Marchant, Robert E. Strong et al. · Biological Psychiatry	Jul 2005	261
2	Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study Nizar El-Khalili, Mark A. Joyce, Sarah D. Atkinson et al. · The International Journal of Neuropsychopharmacology Open access	23 Feb 2010	184
3	Multisite Controlled Study of OROS Methylphenidate in the Treatment of Adolescents With Attention-Deficit/Hyperactivity Disorder Timothy E. Wilens et al. · Archives of Pediatrics and Adolescent Medicine Open access	2006	160
4	A Double-Blind, Placebo-Controlled Study of Aripiprazole Adjunctive to Antidepressant Therapy among Depressed Outpatients with Inadequate Response to Prior Antidepressant Therapy (ADAPT-A Study) Maurizio Fava, David Mischoulon, Dan Vlad Iosifescu et al. · Psychotherapy and Psychosomatics	2012	141
5	ABT-089, A Neuronal Nicotinic Receptor Partial Agonist, for the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Pilot Study Timothy E. Wilens, Marleen H. Verlinden, Lenard A. Adler et al. · Biological Psychiatry	24 Feb 2006	123
6	Gender Differences in 2 Clinical Trials of Adults With Attention-Deficit/Hyperactivity Disorder Reid J. Robison, Frederick W. Reimherr, Barrie K. Marchant et al. · The Journal of Clinical Psychiatry	15 Feb 2008	102
7	A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children Azmi F. Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics Open access	25 Jul 2020	85
8	Disorders usually first diagnosed in infancy, childhood, or adolescence. Charles W. Popper, George D. Gammon, Scott A. West et al.	1994	69
9	Efficacy and safety of topical brepocitinib for the treatment of mild-to-moderate atopic dermatitis: a phase IIb, randomized, double-blind, vehicle-controlled, dose-ranging and parallel-group study Megan N. Landis, Mark Arya, STACY R. SMITH et al. · British Journal of Dermatology Open access	20 Aug 2022	66
10	A Randomized, Double-Blind Study of Once-Daily Extended Release Quetiapine Fumarate (Quetiapine XR) Monotherapy in Patients With Generalized Anxiety Disorder Arifulla Khan, Mark A. Joyce, Sarah D. Atkinson et al. · Journal of Clinical Psychopharmacology	21 Jun 2011	66
11	A Randomized, Placebo-Controlled Trial of Guanfacine Extended Release in Adolescents With Attention-Deficit/Hyperactivity Disorder Timothy E. Wilens, Brigitte Robertson, Vanja Sikirica et al. · Journal of the American Academy of Child & Adolescent Psychiatry	15 Sep 2015	63
12	Changes in Symptoms and Adverse Events After Discontinuation of Atomoxetine in Children and Adults With Attention Deficit/Hyperactivity Disorder Joachim Wernicke, Lenard A. Adler, Thomas J. Spencer et al. · Journal of Clinical Psychopharmacology	Feb 2004	61
13	ADouble-Blind, Placebo-Controlled Withdrawal Trial of Dexmethylphenidate Hydrochloride in Children with Attention Deficit Hyperactivity Disorder L. Eugene Arnold, Ronald L. Lindsay, C. Keith Conners et al. · Journal of Child and Adolescent Psychopharmacology	Dec 2004	51
14	A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder Azmi F. Nasser, Tesfaye Liranso, Toyin Adewole et al. · Journal of Clinical Psychopharmacology Open access	8 May 2021	44
15	Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome Richard B. Lipton, David W. Dodick, Jessica Ailani et al. · Headache The Journal of Head and Face Pain Open access	May 2021	44
16	Safety and tolerability of vortioxetine (15 and 20 mg) in patients with major depressive disorder Paula L. Jacobsen, Linda Harper, Lambros Chrones et al. · International Clinical Psychopharmacology Open access	28 May 2015	29
17	A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD Timothy E. Wilens, Thorsten Klint, Lenard A. Adler et al. · Behavioral and Brain Functions Open access	2008	27
18	Efficacy and Safety of SHP465 Mixed Amphetamine Salts in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled, Forced-Dose Clinical Study Richard H. Weisler, Michael Greenbaum, Valerie K. Arnold et al. · CNS Drugs Open access	15 Jul 2017	26
19	Capillary Index Score in the Interventional Management of Stroke Trials I and II Firas Al-Ali, Thomas A. Tomsick, John J. “Buddy” Connors et al. · Stroke Open access	23 May 2014	24
20	Effect of Lisdexamfetamine Dimesylate on Parent-Rated Measures in Children Aged 6 to 12 Years With Attention-Deficit/Hyperactivity Disorder: A Secondary Analysis Frank A. López, Lawrence D. Ginsberg, Valerie K. Arnold · Postgraduate Medicine	2008	22
21	A Bivalent Omicron-BA.4/BA.5-Adapted BNT162b2 Booster in ≥12-Year-Olds Lisa S. Usdan et al. · Clinical Infectious Diseases Open access	28 Nov 2023	21
22	Optic Nerve Evaluation among Optometrists John M. Spalding, Anthony B. Litwak, CHRISANDRA L. SHUFELT · Optometry and Vision Science	Sep 2000	19
23	Efficacy of Lemborexant in Adults ≥ 65 Years of Age with Insomnia Disorder Valerie K. Arnold, Sonia Ancoli‐Israel, Thien Thanh Dang‐Vu et al. · Neurology and Therapy Open access	15 May 2024	17
24	Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo‐controlled randomized clinical trials Jack D. Schim, Carlton Anderson, Elizabeth Brunner et al. · Headache The Journal of Head and Face Pain Open access	May 2022	7
25	A Phase 3, Randomized Double-Blind Study of the Efficacy and Safety of Low-Dose SHP465 Mixed Amphetamine Salts Extended-Release in Children with Attention-Deficit/Hyperactivity Disorder Gregory W. Mattingly, Valerie K. Arnold, Brian M. Yan et al. · Journal of Child and Adolescent Psychopharmacology Open access	14 Oct 2020	6
26	Aiming for remission in adults with attention-deficit/hyperactivity disorder: The primary care goal Gregory W. Mattingly, Larry Culpepper, Thomas F. Babcock et al. · Postgraduate Medicine	8 Feb 2015	6
27	A Long-Term, Open-Label Safety and Tolerability Study of Lisdexamfetamine Dimesylate in Children Aged 4–5 Years with Attention-Deficit/Hyperactivity Disorder Ann Catherine Childress, Eric Lloyd, Steve A. Johnson et al. · Journal of Child and Adolescent Psychopharmacology Open access	Mar 2022	5
28	Efficacy of Erenumab For the Treatment of Patients with Episodic Migraine with Aura (P4.094) Peter McAllister, Julio Pascual Gómez, Lora McGill et al. · Neurology	10 Apr 2018	3
29	Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old Patricia Winokur et al. · Clinical Infectious Diseases Open access	15 Jan 2026	2
30	Transoral outlet reduction for the treatment of dumping syndrome after Roux-en-Y gastric bypass: a systematic review and meta-analysis Umar Hayat, Raj Shah, Muhammad Umar Kamal et al. · Gastrointestinal Endoscopy Review	25 Sep 2025	2
31	Serving Those Who Served: Tailored Approaches for Military and Veteran Women With CPP Alexander Wang, Julie Taggart, Chensi Ouyang · Clinical Obstetrics & Gynecology	4 Jun 2026	0
32	A proposed grading system for spinal cord arteriovenous shunts Jiaxing Yu, Haohan Lu, Lisong Bian et al. · medRxiv PreprintOpen access	Sep 2023	0
33	Probabilité de réponse à l’administration suivante chez les patients souffrant de migraine et présentant une réponse initiale sous-optimale avec eptinezumab Jack D. Schim, Carlton P. Anderson, Elizabeth Brunner et al. · Revue Neurologique	27 Mar 2023	0
34	Patient Global Impression of Change Related to Improvement in Most Bothersome Symptom Following Treatment With Eptinezumab (S38.009) Roger K. Cady, Lora McGill, Joe Hirman et al. · Neurology	9 Apr 2019	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.